Open AccessGlobal adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase
Author(s) -
Kaleen N. Hayes,
Theresa Burkard,
Stefan Weiler,
Mina Tadrous,
Andrea M. Burden
Publication year - 2021
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0000000000002173
Subject(s) - medicine , sofosbuvir , regimen , adverse effect , hepatitis c , intensive care medicine , ledipasvir , population , ribavirin , hepatitis c virus , immunology , virus , environmental health
Direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C infection (HCV) globally. Exploratory studies to identify potential rare adverse drug events associated with DAAs to optimize their use are scarce.